Background: Periostin, an extracellular matrix protein, contributes to subepithelial 49 thickening in asthmatic airways, and its serum levels reflect airway eosinophilic 50 inflammation. However, the relationship between periostin and the development of airflow 51 limitation, a functional consequence of airway remodeling, remains unknown. 52 Objective: To determine the relationship between serum periostin levels and 53 pulmonary function decline in asthmatic patients on inhaled corticosteroid (ICS) treatment. 54 Methods: 224 asthmatic patients (average age 62.3 years) treated with ICS for at least 55 4 years were enrolled. Annual changes in forced expiratory volume in one second (FEV 1 ), 56 from at least one year after the initiation of ICS treatment to the time of enrollment or later 57 (average 16.2 measurements over 8 years per individual), were assessed. At enrollment, 58 clinical indices, biomarkers including serum periostin, and periostin gene polymorphisms 59 were examined. Associations between clinical indices or biomarkers and a decline in FEV 1 of 60 30 mL·yr -1 or greater were analyzed.
least-square regression lines to data, in which institutions were included as random effects. 205 Unpaired t-and Chi-square tests were performed for comparisons of continuous and 206 dichotomous variables, respectively. When data were not normally distributed, they were log-207 transformed. Data are presented as means (SD) . P values ≤ 0.05 were considered significant.
Results

209
Patients' characteristics 210 Initially, 233 patients were enrolled in this study, but 9 patients were excluded: 5 with a 211 smoking history of more than 10 pack-years and 4 who did not have enough pulmonary respectively. The distribution of ΔFEV 1 in this population is shown in Figure E1 in the Online 217 Repository. Within 2 years after diagnosis, 46% of patients started ICS treatment. At 218 enrollment, 82% of patients took controllers such as long-acting β 2 agonists, leukotriene 219 receptor antagonists, or sustained release theophylline to achieve adequate asthma control.
220
Based on a questionnaire, adherence to medication was satisfactory; 49% of the participants 221 never and 38% seldom forgot to take ICS or other medications. Based on ACT scores, 50% 222 was totally controlled, and 38% scored from 20 to 24, indicating that they were well 223 controlled at enrollment.
224
Serum periostin levels of asthmatic patients [92.8 (38.4 ) ng/mL] were significantly 225 higher than those of healthy subjects [39.1 (24.5) ng/mL, p < 0.001]. The ROC curve analysis 226 was performed to discriminate patients with asthma who were thought to have refractory Th2 227 inflammation despite long-term ICS treatment from healthy subjects. The highest specificity 228 among the 4 cut-off values tested was achieved at 95 ng/mL (0.985) in the comparison study 229 of 224 asthmatic patients and 66 healthy subjects. Therefore a cut-off value of 95 ng/mL was 230 used to define a high serum periostin group, although it had relatively lesser sensitivity 231 (0.379) (see Figure E2 in the Online Repository). In asthmatic patients, 85 patients (38%) had 232 high serum periostin levels (≥ 95 ng/mL). Of the 85 patients, 40 patients (47%) were on treatment step 4, according to the treatment step classification 27 , and 9 patients (11%) were 234 on treatment step 5.
236
Associations between serum periostin levels and greater annual decline in FEV 1 and a 237 decline in FEV 1 of 30 mL•yr -1 or greater 238 In an analysis of continuous values of ΔFEV 1 , greater decline in FEV 1 was associated 239 with higher serum periostin levels at enrollment, treatment step 5, lower ACT scores, 240 incomplete adherence to medications, comorbid or a history of sinusitis, and comorbid 241 diabetes mellitus (Table 3) . When patients were stratified into two groups according to their 242 serum periostin levels, high serum periostin (≥ 95 ng/mL) was also associated with greater 243 decline in FEV 1 (Table 3 ). Of these, high serum periostin was significant after controlling for 244 multiple testing using the false discovery rate (q = 0.03, data not shown in Table 3 ). 30
245
Multivariate analysis revealed that greater decline of FEV 1 was solely associated with high 246 serum periostin (≥ 95 ng/mL) (estimated effect -5.39, 95% confidence interval -10.0 to -0.77, 247 p = 0.02).
248
Fifty-two patients (23%) showed a decline in FEV 1 of 30 mL•yr -1 or greater [mean -249 51.8 (18.4) mL‧yr -1 ] and were considered rapid decliners 31 . When adjusted by confounders, 250 higher serum periostin levels at enrollment, treatment step 5, a history of admission due to 251 asthma exacerbation, higher ICS daily doses, comorbid or a history of sinusitis, and ex-252 smoking were associated with a decline in FEV 1 of 30 mL•yr -1 or greater. High serum 253 periostin (≥ 95 ng/mL) was also associated with a decline in FEV 1 of 30 mL•yr -1 or greater 254 (Table 4) . On multivariate analysis, high serum periostin (≥ 95 ng/mL), treatment step 5, and 255 ex-smoking were independent risk factors for a decline in FEV 1 of 30 mL•yr -1 or greater 256 (Table 4 ).
257
Of the 224 patients, 19 patients were on treatment step 5, and 36 patients took high-258 dose ICS (1,000 μg or higher doses of ICS equivalent to fluticasone propionate daily). When patients were stratified into the high periostin group, the average ΔFEV 1 of patients on 260 treatment step 5 (n = 9) was -41.0 (49.3) mL‧yr -1 , and 7 of them (78%) had excess decline; 261 the average ΔFEV 1 of patients on high-dose ICS (n=18) was -34.3 (39.4) mL‧yr -1 , and 11 of 262 them (61%) had a decline in FEV 1 of 30 mL•yr -1 or greater. Figure 2 ) and ECP levels (r = 0.25, p = 0.0005), 267 ICS-untreated period, i.e. period between onset of asthma and the initiation of ICS therapy (r 268 = 0.16, p = 0.01), daily maintenance doses of ICS at enrollment (r = 0.13, p = 0.05), and a 269 history of admission due to asthma exacerbation (r = 0.15, p = 0.03). Serum periostin levels 270 were significantly higher in patients on high-dose ICS (≥ 1,000 μg daily) than in the 271 remaining patients (110.3 ng/mL vs. 89.5 ng/mL, p = 0.003). Lastly, serum periostin levels 272 were higher in patients with sinusitis than in those without sinusitis (103.9 ng/mL vs. 88.3 273 ng/mL, p = 0.007). Serum periostin levels did not show any seasonal variability or 274 association with age at onset of asthma (data not shown). The frequencies of the 3 tag SNPs and analysis results using dominant and recessive models 282 for serum periostin levels and a decline in FEV 1 of 30 mL•yr -1 or greater are presented in 283 Table 5 . 14 in those with the GC/CC genotype (GG 98.7 ng/mL vs. GC/CC 86.1 ng/mL, p = 0.003).
286
rs1028728 was not associated with serum periostin levels or with the frequency of rapid 287 decliners, but patients with the TT genotype of rs1028728, 4 patients only, showed no 288 significant decline compared with the AA/AT genotype (AA/AT -8.6 mL･yr -1 vs. TT 29.3 289 mL･yr -1 , p = 0.03). Rapid decliners were more frequently observed in patients with the minor 290 A allele of rs9603226 than in the GG genotype (GG 16% vs. AG/AA 30%, p = 0.02). A 291 marked difference in the frequency of rapid decliners was observed when patients were 292 stratified into the high periostin group [GG of rs9630226 (n = 37) 19% vs. AG/AA (n =47) 293 45%, p = 0.01].
294
Discussion
295
To the best of our knowledge, this is the first study to identify a relationship between 296 greater decline in FEV 1 and higher serum periostin levels, particularly if they were 95 ng/mL 297 or more, in asthmatic patients on ICS treatment. It was also shown that high serum periostin, 298 together with treatment step 5 and light ex-smoking, was an independent risk factor for a 299 decline in FEV 1 of 30 mL•yr -1 or greater. In addition, polymorphisms of the POSTN gene, 300 which encodes periostin, were associated with serum periostin levels and a decline in FEV 1 301 of 30 mL•yr -1 or greater in asthmatic patients. These findings suggest that serum periostin 302 may be a useful biomarker for the development of airflow limitation in asthmatic patients on 303 ICS.
304
In this study, despite long-term treatment with ICS with or without other controllers, 305 23% of asthmatic patients were rapid decliners who showed a decline in FEV 1 of 30 mL·yr -1 306 or greater, for which treatment step 5 was an independent risk factor. Adherence to ICS 307 treatment and the frequency of early intervention with ICS did not differ between rapid 308 decliners and non-decliners, although long-term adherence to ICS was undetermined in the 309 present study. In previous studies of patients who were not treated with ICS, severe 310 exacerbation of asthma contributed to greater annual decline of pulmonary function 6,7 , but the 311 exacerbation-related greater annual decline disappeared in an early intervention group with 312 ICS treatment in the START study 6 , which might be interpreted to mean that asthmatic 313 patients on ICS treatment have little risk of accelerated FEV 1 decline. However, since the 314 START study originally recruited mild persistent asthmatic patients, its results cannot simply 315 be applied to severe asthmatic patients. As observed in the present study, there would be a 316 subset of asthmatic patients still at risk of greater annual decline of pulmonary function 317 despite intensive treatment for asthma.
318
Persistent eosinophilic airway inflammation is a key process in irreversible airway 319 obstruction 10 . Indeed, exhaled nitric oxide of 20 ppb or higher is a risk factor for accelerated FEV 1 decline in patients with difficult-to-treat asthma 18 . Studies on novel therapies for the airway epithelium was decreased with ICS treatment 23 . Rather, the elevation of serum 347 periostin in this population may reflect IL-13-mediated inflammation that is partly refractory 348 to ICS, as was reported in a recent study by Jia and colleagues 25 . They showed that, in 349 patients with severe asthma who were treated with high doses ICS (> 1000 µg daily), of the present finding is that high serum periostin is an independent risk factor for greater 356 decline in FEV 1 , providing the first evidence for the potential association between persistent 357 Th2-or IL-13-driven inflammation refractory to ICS treatment and greater decline in FEV 1 , a 358 functional consequence of airway remodeling.
359
Needless to say, current smokers with asthma have more accelerated FEV 1 decline 4 than 360 those not smoking, and current smoking impairs the therapeutic response to ICS or oral 361 corticosteroids 41 . Meanwhile, smoking cessation improves their FEV 1 levels 42 , and ex-362 smokers with asthma with 10 pack-years or more show an intermediate response to short-363 term oral corticosteroid treatment, between current smokers and never-smokers 41 . In the 364 present study, rather unexpectedly, ex-smoking with 10 pack-years or less was still an 365 independent risk factor for a decline in FEV 1 of 30 mL•yr -1 or greater. It should be recognized 366 that even light ex-smoking increases the risk of airway remodeling in asthmatic patients on 367 ICS, and its underlying mechanisms should be clarified.
368
Chronic sinusitis is a well-known comorbidity with severe asthma 43, 44 . In the present 369 study, rapid decliners were more frequently observed in asthmatic patients with sinusitis than 370 those without sinusitis on univariate analysis, and their periostin levels were higher than in 371 patients without sinusitis. In the present study, polypoid lesions in the sinuses were not evaluated by otolaryngologists at enrollment. However, considering that periostin is up-373 regulated in nasal polyp tissue in patients with chronic rhinosinusitis 45 , asthmatic patients 374 with sinusitis may have had severe upper and lower airway inflammation with persistent 375 increases in periostin expression, which may have resulted in a decline in FEV 1 of 30 mL•yr -1 376 or greater. Periostin is a potential molecule that unifies sinusitis and severe asthma.
377
Periostin is encoded on the POSTN gene, which is located on chromosome 13q13.3. 378 rs3829365, which is located at the 5'UTR region that may contain sequences to regulate 379 translation efficiency or mRNA stability, was associated with serum periostin levels. This 380 finding suggests that, besides IL-13, a master regulator of periostin, genetic background 381 partly determines periostin levels, although a replication study would be necessary to confirm 382 this. The minor A allele of rs9603226, located 66 bp upstream of exon 21 in the C-terminal 383 region, was associated with a decline in FEV 1 of 30 mL•yr -1 or greater. In periostin, FAS I 384 domains are thought to be primary binding sites to fibronectin, tenascin-C, and collagen V 21 , 385 whereas the C-terminal region in its intact form may down-regulate the binding activity of 386 periostin to these extracellular matrix proteins 21 . We therefore speculate that the minor A 387 allele of rs9603226 might modify the binding activity at the C-terminal region and facilitate 388 airway remodeling, particularly if the airway is in periostin enriched milieu. Further studies 389 are needed to clarify if these SNPs are functional variants.
390
The age of patients in this study appears to be older than in other Euro-American 391 studies 6, 7, 14, 18, 20, 23, 25 . One reason for the age distribution would be the entry criteria of this 392 study. Another reason would be explained by population aging including population with 393 asthma in Japan. According to a patient survey by the Japanese Ministry of Health, Labour 394 and Welfare in 2008, patients aged 70 to 74 years were the most frequent age group of adult 395 patients with asthma 46 , which is still older than the average age of patients in this study. 
410
In conclusion, serum periostin appears to be a useful biomarker that reflects the 411 development of airflow limitation in patients on prolonged treatment with ICS. POSTN gene 412 polymorphisms may also be helpful for identification of rapid decliners. Adherence to medication, sputum production, and exacerbations ・How often do you forget to take inhaled corticosteroids or other medications? 0: never, 1: seldom, 2: sometimes, 3: often, 4: always ・How often do you produce sputum? 0: never, 1: once in a few days, 2: every morning, 3: every morning and daytime ・How often did you receive systemic steroids due to asthma exacerbations during the recent 6 months? 0: never, 1: once, 2: twice or more GERD: gastro-esophageal reflux disease 556 Figure E2 .
